PHENOTYPIC SCREENING
mRNA IMAGES
mRNA LIFE CYCLE
THE MECHANISM OF ACTION
Anima Biotech mRNA Lightning Platform
We are advancing mRNA Lightning, a novel platform for the discovery of small molecule mRNA drugs and their mechanisms of action. Our differentiated approach combines high scale phenotypic screening that automates millions of experiments in live mRNA biology with MOAi technology using AI to elucidate the mechanism of action of active molecules. We develop our own pipeline and partner with pharma on additional targets.
A unique approach at the intersection of mRNA biology and Artificial Intelligence
mRNA Lightning Platform
Discovery of small molecule mRNA drugs and their mechanisms of action with automated high scale phenotypic screening in live mRNA biology and MOAi technology that uses AI to elucidate the mechanism of action of active molecules.
Discovery of mRNA Biology modulators
Anima's discovery process for selective mRNA biology modulators relies on our proprietary interconnected technologies.
Cerebio runs to produce an in-depth analysis of the mRNA of interest and selects its signature tRNA pair that enables us to visualize mRNA translation in live biology.
Anima's T-Light technologies, TranslationLight and TranscriptLight, are our primary screening assays used for the discovery of mRNA biology modulators. They capture millions of images that show the effect on mRNA biology of hundreds of thousands of compounds from our library.
The images captured during screening are automatically uploaded to the cloud for analysis by BrightNy, which selects the most promising hit compounds using high scale mRNA data analysis. All these technologies feed and interact at every step with our Compass MOAi that runs alongside the discovery process. AI driven MOA elucidation starts as early as hit generation, allowing us to de-risk compounds and progress them at an unprecedented success rate.
We are leveraging AI to understand where and how our small molecules work along the mRNA life cycle
AI driven MOA elucidation
mRNA Biology Modulators Pipeline
With our unique approach, we were able to develop a broad pipeline of small molecule mRNA drugs, advancing 20 discovery programs across therapeutic areas at unparalleled speed and success rate.
Anima wholly owned pipeline programs are in Fibrosis (Collagen I mRNA biology modulators, preclinical stage in lung fibrosis and applicable across many fibrotic diseases), Oncology (c-Myc mRNA biology modulators and mutation agnostic mKras mRNA biology modulators), and Neuroscience (Tau - Alzheimer's disease and Pain - Nav1.7 mRNA biology modulators). In addition to our own pipeline, we established strategic collaborations with Pharma in partnered programs including our collaborations with Lilly, Takeda Pharmaceuticals, and Abbvie.
| Indication | Target | Discovery |
Optimization |
IND enabling |
|
|---|---|---|---|---|---|
Immunology |
|||||
| Lung fibrosis | Collagen-1 | 1 | |||
| Multiple fibrosis | 2 | ||||
| Multiple fibrosis | 3 | ||||
| Undisclosed |  |
4 | |||
Oncology |
|||||
| Solid tumors | c-Myc | 5 | |||
| Lymphoma | 6 | ||||
| c-Myc tumors | 7 | ||||
| Neuroblastoma | Undisclosed | 8 | |||
| mKRAS tumors | mKRAS | 9 | |||
| Undisclosed | |
10 | |||
| Undisclosed | 11 | ||||
Neuroscience |
|||||
| Alzheimer | TAU | 12 | |||
| Pain | Nav 1.7 | 13 | |||
| Undisclosed | 14 | ||||
| Undisclosed |  |
15 | |||
| Undisclosed | 16 | ||||
| Huntington | mHTT | 17 | |||
| Undisclosed |  |
18 | |||
| Undisclosed | 19 | ||||
| Undisclosed | 20 | ||||
| Area | Indication | mRNA modulation | Target | Discovery |
Optimization |
IND enabling |
|
|---|---|---|---|---|---|---|---|
| Immunology | Lung fibrosis | Collagen-1 | 1 | ||||
| Multiple fibrosis | 2 | ||||||
| Multiple fibrosis | 3 | ||||||
| Undisclosed | |
4 | |||||
| Oncology | Solid tumors | c-Myc | 5 | ||||
| Lymphoma | 6 | ||||||
| c-Myc tumors | 7 | ||||||
| Neuroblastoma | Undisclosed | 8 | |||||
| mKRAS tumors | mKRAS | 9 | |||||
| Undisclosed | |
10 | |||||
| Undisclosed | 11 | ||||||
| Neuroscience | Alzheimer | TAU | 12 | ||||
| Pain | Nav 1.7 | 13 | |||||
| Undisclosed | 14 | ||||||
| Undisclosed | |
15 | |||||
| Undisclosed | 16 | ||||||
| Huntington | mHTT | 17 | |||||
| Undisclosed | |
18 | |||||
| Undisclosed | 19 | ||||||
| Undisclosed | 20 | ||||||
17 Scientific Collaborations
15 Peer Reviewed Publications
-
Measuring mRNA translation in neuronal processes and somata by tRNA-FRET
Nucleic Acids Res. 2020 ;46(6):e32 -
A heterogeneous tRNA granule structure exhibiting rapid, bi-directional neuritictransport
Eur J Cell Biol (2018) ; 97 : 168-179. -
Monitoring protein synthesis in single live cancer cells
Integr Biol (2016); 8 :645-53 -
DSCR1 is required for both axonal growth cone extension and steering
J Cell Biol. 2016; 23;213(4):451-62.
Coverage
News & Events
-
AbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology and Immunology Targets
When: Jan. 10th, 2023
AbbVie (NYSE: ABBV), and Anima Biotech (Anima), today announced a collaboration to discover and develop mRNA biology modulators for three targets across Oncology and Immunology. Anima will use its mRNA Lightning platform to discover novel mRNA biology modulators against the collaboration targets providing AbbVie exclusive rights to license and further develop and commercialize the programs.
-
Biotech Showcase 2023
When: Jan. 10th, 2023 - Jan. 11th, 2023
Where: San Francisco, CAAnima Biotech will be attending this year’s Biotech Showcase and is looking forward to connecting with other industry experts. Our chief business officer, Kevin Pong, Ph.D., will give a corporate presentation on Jan. 9th at 9:45 A.M. PST highlighting our unique approach to the discovery of small molecule mRNA drugs.
-
5th RNA Targeting Drug Development Summit
When: Dec. 13th, 2022 - Dec. 15th, 2022
Where: Boston, MAAnima Biotech has been invited to participate in a panel discussion and presentation at the 5th RNA Targeting Drug Development Summit. Our chief business officer, Kevin Pong, Ph.D., will participate in the Biopharma & Investment Partnerships panel – Exploring the Future of RNA Investment & Collaborations Space for Small Molecule on Dec. 14th at 11:50 A.M.